Sequence: Ac-RXRRBRRXRYQFLIRXRBRXRB-acid (B=β-alanine; X=aminohexanoic acid)
Morpholino ASO (Vivo-morpholino / PMO)
| Experiment Id | EXP000810 |
|---|---|
| Paper | Targeting IgE polyadenylation signal with antisense oligonucleotides decreases IgE secretion and pla |
| Peptide | Pip6a |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 12.5 mg/kg (IV tail vein, single dose; serum measured 24 h later) |
| Mixing Ratio | |
| Formulation Format | CPP-conjugated ASO |
| Formulation Components | Pip6a peptide conjugated to 3′ end of vivo-morpholino IgE-PAS ASO (Pip6a-ASO) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | InEps/CreERT2+ humanized IgE mouse model; tamoxifen-induced IgE expression |
| Administration Route | IV (tail vein) |
| Output Type | Serum IgE |
| Output Value | |
| Output Units | |
| Output Notes | Systemic Pip6a-ASO significantly decreased serum humanized IgE vs control ASO 24 h post-injection (Fig 5C). Exact numeric values not provided in text. |
| Toxicity Notes | |
| Curation Notes |